Harnessing the brain’s immune system to fight neurodegeneration

CereSpir Overview

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.



CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015.

CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. more-b